A PHASE Ib STUDY EVALUATING COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH ADVANCED BRAFV600 WILD-TYPE MELANOMA WHO HAVE PROGRESSED DURING OR AFTER TREATMENT WITH ANTI¿PD-1 THERAPY

Administered By

Awarded By

Contributors

Start/End

  • March 17, 2017 - February 28, 2020